title: Effect of 1% and 2% propofol on blood lipids during longterm sedation.
abstract: OBJECTIVE
  To compare the effects of 1% and 2% propofol on the maximum and average lipid levels, the relative frequency of hyperlipidaemia, the propofol dose required to achieve an equivalent degree of sedation, the pharmacodynamic effects at the required infusion rates, and the effect on respiratory function.
  
  
  METHODS
  Open, randomised, parallel group, multicentre comparison study.
  
  
  METHODS
  Intensive care units (ICUs) at the Faculty of Medicine, University of Stellenbosch and at Vergelegen Medicity, Somerset West.
  
  
  METHODS
  Patients who were artificially ventilated for at least 72 hours in the ICUs and who required sedation or analgesia.
  
  
  METHODS
  Continuous intravenous infusion of 1% or 2% propofol to provide an administration rate in the range of 1-4 mg/kg/h. The initial infusion rate was about 2 mg/kg/h, adjusted to achieve the appropriate level of sedation.
  
  
  CONCLUSIONS
  Seventy-five patients were enrolled in the study, of which 72 were evaluable for safety analysis and 58 were evaluable for efficacy analysis. The total daily dose of propofol (ml/day) in the 2% propofol group was about 60% of that in the 1% propofol group, indicating that the lipid load in the 2% propofol group had only slightly more than half the lipid load in the 1% propofol group. Thirteen of 27 patients (48%) in the 2% propofol group had abnormally.
authors.affiliation: Department of Anaesthesiology and Critical Care, University of Stellenbosch, Tygerberg, W Cape.
authors.forename: André
authors.initials: A
authors.lastname: Coetzee
authors.forename: Edward M
authors.initials: EM
authors.lastname: Blaine
authors.forename: D
authors.initials: D
authors.lastname: Labadarios
authors.forename: Robert
authors.initials: R
authors.lastname: Schall
authors.forename: Matthias
authors.initials: M
authors.lastname: Haus
mesh_terms: D000328:Adult; D000368:Aged; D000768:Anesthesia, General; D002784:Cholesterol / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000139:chemically induced* / Q000503:physiopathology; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D015742:Propofol / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D012143:Respiratory Physiological Phenomena / Q000187:drug effects*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
chemical_list: D006993:Hypnotics and Sedatives; D014280:Triglycerides; D002784:Cholesterol; D015742:Propofol